Spectral announces fourth quarter and fiscal 2012 results
TORONTO, March 27, 2013 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its audited financial results for the fourth quarter and year ended December 31, 2012.
-- Continued enrolling patients into the Company's Phase III EUPHRATES trial at a per site rate that is higher than previous sepsis trials. Directed by the Company's Endotoxin Activity Assay (EAA™), which is the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is currently targeted to enroll 306 evaluable patients at up to 60 sites in North America. Contingent on maintaining current enrolment rates and timely site start ups, the trial should be fully enrolled by the end of 2014. -- As of March 25, 2013, 100 patients have been randomized into Spectral's EUPHRATES trial. -- Announced an exclusive distribution agreement with Toray International Italy S.r.l. - a subsidiary of Toray Industries, Inc. - to sell the Company's Endotoxin Activity Assay in combination with Toraymyxin in Saudi Arabia and Turkey. The expansion of commercial jurisdictions with Toray further confirms the outstanding market opportunity for the Company's unique theranostic treatment for septic shock. -- Subsequent to year end, announced that the first interim analysis has been conducted on the initial 76 randomized patients in its EUPHRATES trial. The Data and Safety Monitoring Board (DSMB), consisting of experts in the fields of critical care medicine, infectious disease, nephrology, biostatistics and regulatory affairs, reviewed the totality of the data set for evidence of safety concerns, such as adverse events and/or adverse device effects, related to the use of the Toraymyxin cartridge. The results from the first interim safety analysis by the DSMB state that there are no safety issues to date concerning the application of the Toraymyxin cartridge to patients in the EUPHRATES trial. In addition, the results state that the EUPHRATES clinical protocol appears to be defining the correct target patient population for this study. -- Concluded the reporting period with approximately $10.5 million in cash, cash equivalents and short- term investments. -- Subsequent to year end, on March 7, 2013, the Company announced it entered into a private placement agreement with Toray Industries, Inc. Under the terms of the private placement, Spectral will issue 16,666,667 common shares in the capital of the Company to Toray at a price of $0.30 per common share, for gross proceeds of $5 million. On March 18, 2013 the Company announced that other investors had subscribed for an additional $ 0.6 million under the same terms, bringing the total private placement gross proceeds to $5.6 million. The net proceeds of the private placement will be used to continue to support the Company's EUPHRATES clinical trial and for general operating purposes. Immediately after the closing of the private placement, Toray's investment will represent approximately 12.6% of the issued and outstanding common shares of Spectral, calculated on a non-diluted basis. Closing of the private placement is expected at the beginning of April, 2013 and is subject to the approval of the Toronto Stock Exchange. "2012 was a very important year for the Company," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "We made crucial and significant progress with our Phase III sepsis asset and consequently we are now potentially less than a year away from our second planned interim analysis of the trial data." The second interim analysis will occur after 184 randomized patients have been followed for 28 days. At the second analysis, the trial's DSMB will advise Spectral on the trial's safety, efficacy or futility, with stopping rules in place for efficacy and futility. A sample size recalculation will be done if necessary. Management remains on track to disclose information from the second interim analysis in the first half of 2014. Financial Review Revenue for the three months ended December 31, 2012 was $647,000 compared to $628,000 for the same period in the preceding year. For the year ended December 31, 2012, revenue was $2,589,000 compared to $2,430,000 for the same period in 2011. Revenue was positively impacted by the revised terms of certain EAA™ distribution agreements that took effect during 2012. Conversely, revenues were negatively impacted by the increased strength of the Canadian dollar compared to the U.S. dollar and the Euro. It is anticipated that revenue in 2013 will be consistent with levels achieved in 2012. For the quarter ended December 31, 2012, the Company reported a loss of $2,067,000 compared to a loss of $1,940,000 for the corresponding period in 2011. For the year ended December 31, 2012, Spectral reported a loss of $8,543,000 compared to $6,713,000 for the same period in 2011. The Company's loss was greater for the three and twelve months of 2012 due to higher costs for its EUPHRATES trial. Cash, cash equivalents and short-term investments on hand at December 31, 2012 were $10.5 million. Cash was used during the quarter ended December 31, 2012 to fund operations and for working capital purposes. The total number of shares outstanding for the Company was 113,883,394 as at December 31, 2012. About Spectral Diagnostics Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis with septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis. Toraymyxin has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada. More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit www.spectraldx.com Forward-looking statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. Spectral Diagnostics Inc. Statement of Financial Position (in thousands of Canadian dollars) December 31 December 31 2012 2011 $ $ Assets Current assets Cash and cash equivalents 5,425 13,470 Short-term investment 5,137 5,086 Trade and other receivables 590 515 Inventories 277 295 Prepayments 226 407 11,655 19,773 Non-current assets Property, plant and equipment 497 419 Intangible assets 434 459 931 878 Total assets 12,586 20,651 Liabilities Current liabilities Trade and other payables 1,913 1,610 Deferred revenue 99 102 Total liabilities 2,012 1,712 Equity Share capital 27,101 27,101 Contributed surplus 3,864 3,864 Other equity reserves 8,260 8,082 Deficit (28,651) (20,108) Total equity 10,574 18,939 Total liabilities and equity 12,586 20,651 Spectral Diagnostics Inc. Statement of Loss and Comprehensive Loss For the years ended December 31, 2012 and 2011 (in thousands of Canadian dollars, except for share and per share data) 2012 2011 $ $ Revenue 2,589 2,430 Other income 110 109 Expenses Changes in inventories of finished goods 277 288 and work-in-process Raw materials and consumables used 471 264 Employee benefits 2,944 2,662 Consulting and professional fees 4,619 3,047 Management services 1,013 1,500 Regulatory and investor relations 502 270 Travel and entertainment 772 554 Depreciation and amortization 216 316 Foreign exchange loss 26 2 Other expenses 473 414 11,313 9,317 Operating loss (8,614) (6,778) Finance income 71 65 Loss and comprehensive loss for the year (8,543) (6,713) Basic and diluted loss per common share (0.08) (0.07) Weighted average number of common shares outstanding 113,883,394 90,869,696 Spectral Diagnostics Inc. Statement of Changes in Equity For the years ended December 31, 2012 and 2011 (in thousands of Canadian dollars) Issued Contributed Share-based Total capital surplus compensation Warrants Deficit Equity Number $ $ $ $ $ $ Balance, 80,550,061 17,538 3,696 2,722 5,311 (13,395) 15,872 January 1, 2011 Private 33,333,333 9,563 - - - - 9,563 placement Loss and - - - - - (6,713) (6,713) comprehensive loss for the year Share-based - - - 217 - - 217 compensation Warrants 168 (168) - expired Balance, 113,883,394 27,101 3,864 2,939 5,143 (20,108) 18,939 December 31, 2011 Loss and - - - - - (8,543) (8,543) comprehensive loss for the year Share-based - - - 178 - - 178 compensation Balance, 113,883,394 27,101 3,864 3,117 5,143 (28,651) 10,574 December 31, 2012 Spectral Diagnostics Inc. Statement of Cash Flows For the years ended December 31, 2012 and 2011 (in thousands of Canadian dollars) 2012 2011 $ $ Cash flow provided by (used in) Operating activities Loss and comprehensive loss for the (8,543) (6,713) year Adjustments for: Depreciation on property, plant, 191 173 and equipment Amortization of intangible assets 25 143 Share-based compensation 178 217 Changes in items of working capital : Trade and other receivables (75) 80 Inventories 18 (86) Prepayments 181 (376) Trade and other payables 303 288 Deferred revenue (3) 1 Net cash used in operating activities (7,725) (6,273) Investing activities Property, plant and equipment (269) (66) expenditures Redemption of short-term investment 5,086 5,021 Purchase of short-term investment (5,137) (5,086) Net cash used in investing activities (320) (131) Financing activities Private placement - 9,563 Net cash provided by financing - 9,563 activities (Decrease) increase in cash and cash (8,045) 3,159 equivalents Cash and cash equivalents, beginning 13,470 10,311 of year Cash and cash equivalents, end of 5,425 13,470 year Anthony Businskas Executive Vice President and CFO 416-626-3233 ext. 2200 Adam Peeler Investor Relations TMX Equicom 416-815-0700 ext. 225 email@example.com SOURCE: Spectral Diagnostics Inc. To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/March2013/27/c8617.html CO: Spectral Diagnostics Inc. ST: Ontario NI: BTC CPR ELE ERN -0- Mar/27/2013 11:00 GMT